Abiomed, Biosense Webster, Cerenovus now all known as Johnson & Johnson MedTech

Michael Walter | September 11, 2024 | Cardiovascular Business | Mergers & Acquisitions

Johnson & Johnson has officially completed a major transition, announcing that Biosense Webster, Abiomed, Cerenovus and some of its other healthcare technology companies will now go by the name Johnson & Johnson MedTech.

Johnson & Johnson first announced its agreement to acquire Biosense Webster for $400 million in shares back in 1997, and Cerenovus was launched in 2017 after the company combined its acquisitions of Pulsar Vascular and Neuravi. The decision to buy Abiomed, meanwhile, came in November 2022.

Now, these companies—in addition to Ethicon and DePuy Synthes—are all under the Johnson & Johnson umbrella.

“By bringing our medtech businesses together under the Johnson & Johnson name, the scale of our impact in healthcare will be even more apparent, unlocking new opportunities for us to strengthen our competitiveness,” Tim Schmid, Johnson & Johnson executive vice president and worldwide chairman of medtech, said in a statement. “While Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and Cerenovus will now go by Johnson & Johnson MedTech, we will continue to honor the legacies of these brands by maintaining the products, services and approach to collaboration that made them some of the most trusted names in healthcare.”

This change is expected to hit social media pages and other marketing materials in the weeks ahead. The company emphasized that this “will have no impact on the Johnson & Johnson MedTech portfolio.”

How the move impacts other recent acquisitions

In May, Johnson & Johnson finalized its acquisition of Shockwave Medical, the California-based company known for its intravascular lithotripsy technology, for $13 billion. While it is now operating as a business unit within Johnson & Johnson MedTech, it was not one of the companies included in this latest name change announcement.

Another recently announced Johnson & Johnson transaction, the company’s acquisition of V-Wave for up to $1.7 billion, has not yet been finalized.

Johnson & Johnson to acquire heart failure specialists V-Wave for up to $1.7B

Edwards continues valve-focused M&A streak by acquiring promising TAVR startup

Intravascular lithotripsy, the technology at heart of $13B acquisition, linked to positive real-world data

Medical device company raises another $105M for new-look heart pump

It’s official: Johnson & Johnson completes $13B Shockwave Medical acquisition

Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Major association of physicians presents itself as a go-to alternative vs. the government on vaccine expertise

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations.

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.